DWA
ATOS icon

Delos Wealth Advisors’s Atossa Therapeutics ATOS Stock Holding History

Delos Wealth Advisors’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7
Closed -$152 – 201
2024
Q3 		$152 Hold
7
– – ﹤0.01% 182
2024
Q2 		$119 Hold
7
– – ﹤0.01% 335
2024
Q1 		$180 Hold
7
– – ﹤0.01% 335
2023
Q4 		$88 Hold
7
– – ﹤0.01% 329
2023
Q3 		$79 Hold
7
– – ﹤0.01% 369
2023
Q2 		$126 Hold
7
– – ﹤0.01% 363
2023
Q1 		$73 Hold
7
– – ﹤0.01% 383
2022
Q4 		$53 Hold
7
– – ﹤0.01% 392
2022
Q3 		$0 Hold
7
– – ﹤0.01% 293
2022
Q2 		$0 Hold
7
– – ﹤0.01% 230
2022
Q1 		$0 Hold
7
– – ﹤0.01% 259
2021
Q4 		$0 Hold
7
– – ﹤0.01% 436
2021
Q3 		$0 Hold
7
– – ﹤0.01% 212
2021
Q2 		$1K Buy
+7
New +$371 ﹤0.01% 154

Other funds holding ATOS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Delos Wealth Advisors's ATOS Position: Q4 2024 in Review

Delos Wealth Advisors sold out of Atossa Therapeutics (ATOS) in Q4 2024, closing a stake of 7 shares — an estimated $152 sold.

Delos Wealth Advisors first reported a position in ATOS in Q2 2021 and held it in 14 quarters. The position peaked at $1K in Q2 2021. 86 funds tracked by Wall St. Rank hold ATOS as of Q4 2024.

  • Delos Wealth Advisors reported no remaining Atossa Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Delos Wealth Advisors sold 7 Atossa Therapeutics shares in Q4 2024, an estimated $152.
  • Delos Wealth Advisors first reported a position in Atossa Therapeutics in Q2 2021 and held it in 14 quarters.
  • Delos Wealth Advisors's Atossa Therapeutics position peaked at $1K in Q2 2021.
  • 86 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q4 2024.

Based on Delos Wealth Advisors's 13F filing for Q4 2024, filed 12 Feb 2025.